drugset / Trial / NCT00441519

A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin

NCT00441519

Phase 1 Completed 80 enrolled POZEN
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet

Timeline

Start
2007-02
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg
Subject Aspirin Small molecule 325 mg
Subject Omeprazole Other / unclassified 20 mg

Indications

No indication recorded.